课题基金 / 基金详情

BRP-39/YKL-40 in Th2 Inflammation and Asthma

BRP-39/YKL-40 in Th2 Inflammation and Asthma
BRP-39/YKL-40 在 Th2 炎症和哮喘中的作用
批准号:
8789047
负责人:
Jack A Elias
金额:
$15.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-01-18 至 2014-12-31
关键词:

项目摘要

项目成果

Jack A Elias的其他基金

相似基金

相关文献

中文摘要
翻译
说明(由申请人提供):人体内不存在几丁质和几丁质合成酶。然而,几丁质酶和几丁质酶样蛋白(C/CLP)最近得到了重视。这包括真正的几丁质酶和缺乏几丁质酶活性的部分,如乳腺消退蛋白39 (BRP-39)及其人类同源物YKL-40。BRP-39和YKL-40在多种疾病中以夸张的方式表达。然而,它们在哺乳动物或人类生物学中的作用几乎一无所知。我们研究了BRP-39在变应性炎症中的调控作用。这些研究表明(a) BRP-39在Th2和il -13诱导的炎症部位显著诱导,(b) BRP-39-/-小鼠在Th2和il -13诱导的炎症和重塑中存在显著缺陷,这与T细胞和巨噬细胞凋亡和Fas表达增强有关,(c) BRP-39/ ykl -40诱导的细胞保护与蛋白激酶b /Akt活化增强有关。他们还证明BRP-39/YKL-40结合IL-13受体(R)a2,并通过IL-13Ra2依赖机制激活有丝分裂原活化蛋白激酶(MAPK)和PKB/Akt。最后,他们通过证明YKL-40在严重哮喘患者的血清和肺部中含量过高,以及几丁质酶3样1是哮喘易感基因,强调了这些发现与人类的相关性。这就引出了下面的假设。假设:1。BRP-39/YKL-40在适应性Th2炎症和重塑的发病过程中受到诱导,并在其发病机制中发挥关键和选择性作用。2. BRP-39和YKL-40是T细胞和巨噬细胞凋亡/细胞死亡的重要调节因子。3. BRP-39和YKL-40通过涉及IL-13Ra2、MAPK和/或PKB/Akt的途径介导其组织反应。为了验证这一假设,我们提出:AIM 1。表征BRP-39在Th2和Th1炎症和重塑中的表达和作用。目标2。表征血清、组织、上皮和巨噬细胞来源的BRP-39/YKL-40在Th2和il -13诱导的炎症和重塑中的相对贡献。目标3。明确BRP-39/YKL-40与IL-13Ra2的相互作用,以及IL-13Ra2在BRP-39/YKL-40生物学效应发病机制中的作用。目标4。描述BRP-39-/-小鼠中夸大的T细胞和巨噬细胞凋亡/细胞死亡反应的机制以及这种细胞死亡途径与人类的相关性。
英文摘要
DESCRIPTION (provided by applicant): Chitin and chitin synthase do not exist in man. However, chitinases and chitinase-like proteins (C/CLP) have recently been appreciated. This includes true chitinases and moieties that lack chitinase activity like breast regression protein-39 (BRP-39) and its human homologue YKL-40. BRP-39 and YKL-40 are expressed in an exaggerated fashion in a variety of diseases. However, virtually nothing is known about their roles in mammalian or human biology. We studied the regulation and roles of BRP-39 in allergic inflammation. These studies demonstrate that (a) BRP-39 is prominently induced at sites of Th2 and IL-13-induced inflammation, (b) BRP-39-/- mice have a significant defect in Th2 and IL-13-induced inflammation and remodeling that is associated with enhanced T cell and macrophage apoptosis and Fas expression and (c) BRP-39/YKL-40-induced cytoprotection is associated with enhanced protein kinase B/Akt activation. They also demonstrate that BRP-39/YKL-40 binds to IL-13 receptor (R)a2 and activates mitogen activated protein kinases (MAPK) and PKB/Akt via an IL-13Ra2- dependent mechanism. Lastly, they highlight the human relevance of these findings by demonstrating that YKL-40 is found in exaggerated quantities in the serum and lungs from severe asthmatics and that chitinase 3- like 1 is an asthma susceptibility gene. This led us to the following hypothesis. HYPOTHESIS: 1. BRP-39/YKL-40 is induced during and plays a critical and selective role in the pathogenesis of adaptive Th2 inflammation and remodeling. 2. BRP-39 and YKL-40 are important regulators of T cell and macrophage apoptosis/cell death. 3. BRP-39 and YKL-40 mediate their tissue responses via a pathway(s) that involves IL-13Ra2, MAPK and or PKB/Akt. To test this hypothesis we propose to: AIM 1. Characterize the expression and roles of BRP-39 in Th2 and Th1 inflammation and remodeling. AIM 2. Characterize the relative contributions of serum and tissue and epithelial- and macrophage-derived BRP-39/YKL-40 in Th2 and IL-13-induced inflammation and remodeling. AIM 3. Define the interactions of BRP-39/YKL-40 and IL-13Ra2 and the roles of IL-13Ra2 in the pathogenesis of the biologic effects of BRP-39/YKL-40. AIM 4. Characterize the mechanisms of the exaggerated T cell and macrophage apoptosis/cell death responses in BRP-39-/- mice and the relevance of this cell death pathway to humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Differential Roles of Chi3l1 and its receptors in COPD and IPF
Differential Roles of Chi3l1 and its receptors in COPD and IPF
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney Transplantation
  • 批准号:
    8499409
  • 项目类别:
  • 资助金额:
    $62.22万
  • 财政年份:
    2011
  • 负责人:
    Jack A Elias
  • 依托单位:
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney Transplantation
  • 批准号:
    8320196
  • 项目类别:
  • 资助金额:
    $65.81万
  • 财政年份:
    2011
  • 负责人:
    Jack A Elias
  • 依托单位:
国内基金
海外基金
普罗布考抑制SLC39A14引起的铁死亡在防治阿霉素DIC中的机制研究
  • 批准号:
    2026JJ81927
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    刘佩英
  • 依托单位:
基于“痰浊致呆”理论探讨涤痰汤调控CD39-A3AR-CREB信号轴改善血管性痴呆的分子机制
CD39+CD8+T细胞通过腺苷-PD-1协同通路介导弥漫大B细胞淋巴瘤免疫逃逸的机制及靶向干预研究
补肾活血方靶向SLC39A14改善子宫内膜容受性的机制研究
  • 批准号:
    2026JJ82160
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    罗岚
  • 依托单位: